's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
»'s Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » BMSN -- Bio-Matrix Scientific Group

 - UBBFriend: Email this page to someone!    
Author Topic: BMSN -- Bio-Matrix Scientific Group

Rate Member
Icon 1 posted      Profile for pennybuilder     Send New Private Message       Edit/Delete Post   Reply With Quote 
Operational Plan set forth by BMSN (Regen):

Month 1-2: Assembly of Team. Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. - DONE (See post# 5463)

Month 1-4: In-licensing of Intellectual Property. The Company having already assessed over 20,000 issued patents and having compiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses on issued patents that have already passed preclinical studies but are not under clinical development.- DONE

SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells.

Month 3-6: Interaction with Regulatory Agencies. Regen intends to develop data packages for each of the technologies and initiate interaction with Regulatory Agencies such as the FDA for initiation of trials.- DONE (Clinartis!)

Month 6-18: Clinical Implementation. Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy. - Up Next!

According to David Koos, Chairman & CEO of Bio-Matrix, “HemaXellerate™ may provide an ideal therapeutic for bone marrow failure based upon: (1) regulating secretion of cytokines as biologically needed; (2) producing long-term, localized growth factors that alleviate the need for drugs; and (3) actively repairing the blood producing stem cell environment.”

A spokesperson for the Company said Regen intends to file an Investigational New Drug (IND) Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.

Month 18-24: Exit. It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline. - $$ $Patience Makes Bank$$$$

As I've mentioned before, it seems as though they are actually ahead of schedule and have BIG aspirations for the NEAR future. IMHO

$$ $Long and Strong...GO BMSN$$$$

IP: Logged | Report this post to a Moderator

Rate Member
Icon 1 posted      Profile for pennybuilder     Send New Private Message       Edit/Delete Post   Reply With Quote 
Doing well today, 10X more buys then sells. [Big Grin]
IP: Logged | Report this post to a Moderator

Quick Reply

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins

Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | Message Board Home

© 1997 - 2021 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2